Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO 2019 Congress

Circulating tumour cell counts as clinical trial endpoint in prostate cancer?

Yes

Date

29 Sep 2019

Session

Circulating tumour cell counts as clinical trial endpoint in prostate cancer?

Topics

Tumour Site

Prostate Cancer

Presenters

Davis Olmos

Authors

D. Olmos

Author affiliations

  • Department Of Cancer Clinical Research, Spanish National Cancer Research Centre (CNIO), Madrid and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Madrid/ES

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

Resources from the same session

Introduction and 1st vote

Presenter: Henrik Grönberg

Session: Circulating tumour cell counts as clinical trial endpoint in prostate cancer?

Resources:

Slides

Webcast

No

Presenter: David Lorente Estelles

Session: Circulating tumour cell counts as clinical trial endpoint in prostate cancer?

Resources:

Slides

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.